Sep 10 2014
Senesco Technologies, Inc., a clinical-stage company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, announced today a corporate rebranding under which the Company will change its name to Sevion Therapeutics, Inc.
The Company will continue to trade as SNTI until a new ticker symbol is obtained. The rebranding and new corporate identity are first steps in fulfilling the Company’s goal of becoming a preeminent, next-generation biologics company with best- and first-in-class product candidates and technologies.
“Sevion brings together several cutting-edge platform technologies. Novel antibody discovery systems and scaffolds address important therapeutic targets previously inaccessible with biologics, including GPCRs and ion channels, and nucleic acid-loaded nanoparticles leverage our deep understanding of the eIF5A ‘apoptosis gene’,” said Ronald Martell, chief executive officer. “This new corporate identity will allow us to build broader awareness of our innovative platforms and objectives to advance a high-value pipeline of proprietary and partnered product candidates.”
Mr. Martell concluded: “As we launch this new identity, our strategy will focus on several components, including our clinical asset SNS01-T, moving two promising antibodies toward Investigational New Drug (IND) status and leveraging our pipeline and platforms through partnerships, while looking to in-licensing opportunities that are consistent with our therapeutic areas and scientific focus.
Source: http://www.seviontherapeutics.com/